Teva has reached an agreement with the Israel Tax Authority to resolve all pending litigation by agreeing to pay $750 million in installments from 2024 to 2029. Additionally, Teva will pay an extra 5%-7% in corporate taxes on any future dividends or equity repurchases, up to $500 million.